Table 3.
CKDUA cohort split according to possible underlying aetiology
| Variable | True CKDUA (216) | CKD of possible hypertensive/ diabetic aetiology (H/D CKD) (182) | P-value |
|---|---|---|---|
| Age, years | 71.3 (61.8–77.8) | 72.0 (63.2–79.3) | 0.267 |
| Male | 130 (60.2) | 109 (59.9) | 0.952 |
| White | 208 (96.3) | 175 (96.2) | 0.941 |
| BMI, kg/m2 | 26.3 (23.2–31.6) | 29.2 (26.0-33.9) | < 0.001 |
| SBP, mmHg | 139.5 (125–150) | 140 (125-156.5) | 0.207 |
| DBP, mmHg | 75 (68–80) | 70 (65–80) | 0.215 |
| Hypertension | 166 (76.9) | 175 (96.2) | < 0.001 |
| Diabetes | 18 (8.3) | 47 (25.8) | < 0.001 |
| Angina | 46 (21.3) | 28 (15.4) | 0.131 |
| MI | 30 (13.9) | 21 (11.5) | 0.485 |
| CCF | 35 (16.2) | 32 (17.6) | 0.714 |
| CVA | 12 (5.6) | 13 (7.1) | 0.516 |
| PVD | 22 (10.2) | 25 (13.7) | 0.274 |
| Cancer | 34 (15.7) | 23 (12.6) | 0.379 |
| Liver disease | 3 (1.4) | 6 (3.3) | 0.202 |
| COPD | 41 (19.0) | 36 (19.8) | 0.841 |
| ACEi/ARB | 80 (40.4) | 119 (67.2) | < 0.001 |
| Statin | 93 (47) | 103 (58.2) | 0.03 |
| Creatinine, µmol/L | 173 (129–256) | 171 (132–236) | 0.879 |
| eGFR, ml/min/1.73m2 | 31 (20–43) | 30 (21–45) | 0.998 |
| Annual rate of change of eGFR, ml/min/1.73m2/year | -0.72 (-2.65 to 1.01) | − 0.76 (-2.1 to 1.10) | 0.641 |
| uPCR, g/mol | 18.6 (10.2–56.4) | 20.8 (10.4–66.3) | 0.586 |
| Albumin, g/L | 43 (41–45) | 43 (41–45) | 0.265 |
| Hb, g/L | 123 (111–132) | 121 (112–134) | 0.410 |
| Calcium, mmol/L | 2.32 (2.22–2.41) | 2.28 (2.19–2.37) | 0.019 |
| Phosphate, mmol/L | 1.10 (0.98–1.27) | 1.10 (0.96–1.26) | 0.482 |
| C3, g/L | 1.18 (0.95–1.37) | 1.22 (1.09–1.42) | 0.044 |
| C4, g/L | 0.25 (0.20–0.31) | 0.25 (0.20–0.31) | 0.865 |
|
CTD screen abnormality |
35 (21.5) | 41 (29.9) | 0.094 |
|
Serum electrophoresis abnormality |
13 (6.0) | 12 (6.6) | 0.754 |
| Positive family history | 4 (1.9) | 0 (0) | 0.065 |
| Renal cysts on imaging | 57 (36.8) | 55 (42) | 0.368 |
| Right kidney size, cm | 9.6 (8.8–10.5) | 9.9 (9.0-10.5) | 0.328 |
| Left kidney size, cm | 9.6 (8.7–10.5) | 10.0 (9.3–10.9) | 0.026 |
| RRT | 31 (14.4) | 25 (13.7) | 0.846 |
| 5 year RRT rate | 25 (11.6) | 21v(11.5) | 0.991 |
| Mortality | 109 (50.5) | 111 (61) | 0.035 |
| 5 year mortality rate | 58 (26.9) | 69 (37.9) | 0.018 |
|
Follow up duration, months |
47 (22–83) | 43 (20–79) | 0.719 |
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCF, congestive cardiac failure; COPD, chronic obstructive pulmonary disease; CTD, connective tissue disease screen; CVA, cerebrovascular accident; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; MI, myocardial infarction; PVD, peripheral vascular disease; RRT, renal replacement therapy; SBP, systolic blood pressure
Categorical values presented as number (percentage), continuous variables as median (interquartile ran